<DOC>
	<DOCNO>NCT01250743</DOCNO>
	<brief_summary>The purpose pilot study learn whether high dos ascorbic acid ( vitamin c ) , give intravenously patient chronic hepatitis due infection genotype 1 version hepatitis C virus , safe , well-tolerated able reduce amount virus circulate patient ' blood .</brief_summary>
	<brief_title>A Pilot Study High-Dose , Intravenous Ascorbic Acid ( Vitamin C ) Treat Hepatitis C</brief_title>
	<detailed_description>Hepatitis C virus ( HCV ) chronically infect 1 % 3 % world 's population , include 3.9 million infected patient United States , estimate 36,000 new case US year . 70-85 % infected individual develop chronic infection complicate chronic liver disease next 20 30 year , tenth lead cause death US . HCV implicate development hepato-cellular carcinoma . Chronic HCV hepatitis frequent reason liver transplantation . HCV genotype 1 common genetic variant HCV cause HCV hepatitis US . It respond less well conventional anti-HCV treatment HCV genotype , 60 % genotype 1 patient fail conventional therapy due virus 's resistance treatment and/or due toxic side effect therapy . Extracellular level ascorbic acid ( vitamin c ) attainable high-dose , intravenous administration , report vitro vivo anti-cancer anti-viral effect human animal . Ascorbic acid briefly generates extracellular hydrogen peroxide , oxidative stress specifically toxic cancer cell cell infected virus , include HCV , normal cell . High-dose , intravenous ascorbic acid give large number patient , particularly cancer patient , anecdotal report good safety occasional benefit . Given foregoing , investigator propose sufficient rationale careful pilot study safety anti-viral efficacy infuse ascorbic acid HCV genotype 1 hepatitis .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>hepatitis C , genotype 1 fail treatment interferonalpha ribavirin abstain alcohol consumption duration study cirrhosis decompensated liver disease glucose6phosphate dehydrogenase deficiency AST ALT 5 time upper limit normal platelet le 125,000 diabetes mellitus alcohol and/or drug abuse within 1 year screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>genotype 1</keyword>
</DOC>